BPMC
Income statement / Annual
Last year (2023), Blueprint Medicines Corporation's total revenue was $249.38 M,
an increase of 22.22% from the previous year.
In 2023, Blueprint Medicines Corporation's net income was -$506.98 M.
See Blueprint Medicines Corporation,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$249.38 M
|
$204.04 M
|
$180.08 M
|
$793.74 M
|
$66.51 M
|
$44.52 M
|
$21.43 M
|
$27.77 M
|
$11.40 M
|
$0.00
|
| Cost of Revenue |
$12.80 M |
$17.81 M |
$17.93 M |
$425,000.00 |
$0.00 |
$243.62 M |
$144.69 M |
$81.13 M |
$48.59 M |
$31.84 M |
| Gross Profit |
$236.58 M |
$186.22 M |
$162.15 M |
$793.31 M |
$66.51 M |
-$199.10 M |
-$123.26 M |
-$53.36 M |
-$37.19 M |
-$31.84 M |
| Gross Profit Ratio |
0.95 |
0.91 |
0.9 |
1 |
1 |
-4.47 |
-5.75 |
-1.92 |
-3.26 |
0 |
| Research and Development
Expenses |
$427.72 M
|
$477.42 M
|
$601.03 M
|
$326.86 M
|
$331.45 M
|
$243.62 M
|
$144.69 M
|
$81.13 M
|
$48.59 M
|
$31.84 M
|
| General & Administrative
Expenses |
$278.24 M
|
$219.27 M
|
$181.79 M
|
$148.34 M
|
$96.39 M
|
$47.93 M
|
$27.99 M
|
$19.22 M
|
$14.46 M
|
$7.89 M
|
| Selling & Marketing
Expenses |
$16.90 M
|
$18.10 M
|
$13.50 M
|
$9.40 M
|
$3.30 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$295.14 M
|
$237.37 M
|
$195.29 M
|
$157.74 M
|
$96.39 M
|
$47.93 M
|
$27.99 M
|
$19.22 M
|
$14.46 M
|
$7.89 M
|
| Other Expenses |
$0.00 |
$8.95 M |
$7.80 M |
-$366,000.00 |
-$100,000.00 |
$10.46 M |
$3.35 M |
$551,000.00 |
-$429,000.00 |
-$98,000.00 |
| Operating Expenses |
$722.86 M |
$723.74 M |
$804.13 M |
$484.60 M |
$427.84 M |
$291.55 M |
$172.67 M |
$100.35 M |
$63.04 M |
$39.73 M |
| Cost And Expenses |
$735.66 M |
$741.55 M |
$822.06 M |
$485.03 M |
$427.84 M |
$291.55 M |
$172.67 M |
$100.35 M |
$63.04 M |
$39.73 M |
| Interest Income |
$0.00 |
$17.75 M |
$2.39 M |
$6.60 M |
$13.73 M |
$10.64 M |
$3.43 M |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$16.77 M |
$0.00 |
$0.00 |
$13.73 M |
$73,000.00 |
$221,000.00 |
$469,000.00 |
$696,000.00 |
$453,000.00 |
| Depreciation &
Amortization |
$11.67 M
|
$20.10 M
|
$12.79 M
|
$12.35 M
|
$10.25 M
|
$4.25 M
|
$1.58 M
|
$1.58 M
|
$948,000.00
|
$622,000.00
|
| EBITDA |
-$470.36 M
|
-$515.42 M
|
-$628.30 M
|
$308.71 M
|
-$356.07 M
|
-$242.78 M
|
-$149.67 M
|
-$70.44 M
|
-$51.13 M
|
-$39.11 M
|
| EBITDA Ratio |
-1.89 |
-2.63 |
-3.56 |
0.39 |
-5.43 |
-5.31 |
-6.9 |
-2.59 |
-4.57 |
0 |
| Operating Income Ratio
|
-1.95
|
-2.69
|
-3.6
|
0.38
|
-5.51
|
-5.55
|
-6.98
|
-2.65
|
-4.65
|
0
|
| Total Other
Income/Expenses Net |
-$19.74 M
|
-$14.76 M
|
$897,000.00
|
$6.23 M
|
$13.63 M
|
$10.39 M
|
$3.13 M
|
$82,000.00
|
-$1.13 M
|
-$551,000.00
|
| Income Before Tax |
-$506.02 M |
-$552.28 M |
-$641.08 M |
$314.94 M |
-$347.69 M |
-$236.64 M |
-$148.12 M |
-$72.50 M |
-$52.77 M |
-$40.29 M |
| Income Before Tax Ratio
|
-2.03
|
-2.71
|
-3.56
|
0.4
|
-5.23
|
-5.32
|
-6.91
|
-2.61
|
-4.63
|
0
|
| Income Tax Expense |
$968,000.00 |
$5.24 M |
$3.00 M |
$1.06 M |
-$18.99 M |
$10.46 M |
$1.99 M |
-$562,000.00 |
-$681,000.00 |
$355,000.00 |
| Net Income |
-$506.98 M |
-$557.52 M |
-$644.09 M |
$313.88 M |
-$328.70 M |
-$236.64 M |
-$148.12 M |
-$72.50 M |
-$52.77 M |
-$40.29 M |
| Net Income Ratio |
-2.03 |
-2.73 |
-3.58 |
0.4 |
-4.94 |
-5.32 |
-6.91 |
-2.61 |
-4.63 |
0 |
| EPS |
-8.37 |
-9.35 |
-11.01 |
5.76 |
-6.87 |
-5.39 |
-3.92 |
-2.64 |
-2.89 |
-3.08 |
| EPS Diluted |
-8.37 |
-9.35 |
-11.01 |
5.59 |
-6.87 |
-5.39 |
-3.92 |
-2.64 |
-2.89 |
-3.08 |
| Weighted Average Shares
Out |
$60.56 M
|
$59.64 M
|
$58.52 M
|
$54.53 M
|
$47.83 M
|
$43.87 M
|
$37.79 M
|
$27.49 M
|
$18.24 M
|
$13.08 M
|
| Weighted Average Shares
Out Diluted |
$60.56 M
|
$59.64 M
|
$58.52 M
|
$56.17 M
|
$47.83 M
|
$43.87 M
|
$37.79 M
|
$27.49 M
|
$18.24 M
|
$13.08 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
